Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Envoy Medical, Inc. filings document a hearing-health company with Class A common stock and redeemable warrants listed on Nasdaq. Its regulatory record covers operating results, financial-condition updates, registration statements for securities offerings, warrant and pre-funded warrant structures, and disclosures related to its status as an emerging growth company.
Company filings also include proxy materials for director elections, auditor ratification, executive compensation, equity incentive and employee stock purchase plan amendments, and Nasdaq share-issuance approvals. Form 8-K disclosures address material agreements, auditor changes, compensatory arrangements, Nasdaq listing compliance, and risk-related matters such as going-concern language in audit reports.
Envoy Medical, Inc. reports that Nasdaq has granted an additional 180-day period, until November 16, 2026, to regain compliance with the Nasdaq Capital Market’s $1.00 minimum bid price requirement for its Class A common stock.
The company previously failed to meet this bid price by the initial May 18, 2026 deadline, after its shares traded below $1.00 for 30 consecutive business days. Envoy remains otherwise in compliance with Nasdaq Capital Market listing standards and has notified Nasdaq that it intends to cure the deficiency, including potentially implementing a reverse stock split if needed.
Envoy Medical, Inc. reported results of its 2026 Annual Meeting of Stockholders held on May 12, 2026. Stockholders approved amendments to the 2023 Equity Incentive Plan and the 2023 Employee Stock Purchase Plan.
The Equity Incentive Plan amendment authorizes an additional 6,000,000 shares of Class A Common Stock for awards, while the Employee Stock Purchase Plan amendment authorizes an additional 1,200,000 shares for employee purchases. Both amendments became effective upon stockholder approval.
Stockholders also elected Brent T. Lucas and Susan J. Kantor as directors, with each nominee receiving over 46.9 million votes "for" and modest withheld and broker non-vote totals, as detailed in the voting results.
Envoy Medical, Inc. Schedule 13G reports that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 7,683,798 shares of Class A Common Stock, representing 9.99% of the class as of March 31, 2026. The disclosed holdings include 33,798 shares that may be acquired within sixty days through the exercise of convertible securities. The filing shows shared voting and dispositive power over the 7,683,798 shares and reports no sole voting or dispositive power.
Envoy Medical ownership disclosure: Bleichroeder and related filers report beneficial ownership of 7,839,000 shares of Class A common stock, equal to 9.99% of the class. The holding comprises 6,250,000 owned shares and 1,589,000 shares issuable upon exercise of warrants, with warrant exercises subject to a 9.99% Beneficial Ownership Limitation.
The filing states that without the 9.99% limit the filer would be deemed beneficial owner of 16,250,000 shares (including 10,000,000 warrants), or approximately 18.7% of outstanding common stock. Reporting persons are Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach.
ENVOY MEDICAL, INC. reports that Ayrton Capital LLC, Alto Opportunity Master Fund (Segregated Master Portfolio B) and Waqas Khatri each hold 2,457,963 shares of Class A common stock as of March 31, 2026, reflecting 3.10% of the class. These shares represent common stock issuable on exercise of warrants held by the reporting persons and are subject to a 9.99% beneficial ownership blocker. The filing states there were 76,881,110 shares outstanding as of March 20, 2026, per the issuer's 10-K; percentages are calculated using that figure and the issuable warrants. The reporting persons are the Fund, its Investment Manager Ayrton Capital LLC, and Waqas Khatri as managing member.
Envoy Medical reported a Q1 2026 net loss of $4,351, slightly improved from $4,998 a year earlier, on very modest net revenue of $39. Operating expenses rose to $5,998, driven mainly by research and development for its fully implanted Acclaim cochlear implant.
Cash jumped to $25,251 from $3,739 at year-end 2025, after the February 2026 equity offering raised net proceeds of $27,782. That deal issued 47.9 million common shares, 27.1 million pre-funded warrants, and 120 million-plus Series A warrants.
Despite the stronger balance sheet, Envoy still discloses “substantial doubt” about its ability to continue as a going concern, citing ongoing losses and dependence on future financings and warrant exercises. The company ended the quarter with an accumulated deficit of $319,097 and 76,881,110 Class A shares outstanding.
Envoy Medical reported first quarter 2026 results and key milestones as it advances its fully implanted Acclaim cochlear implant toward FDA approval. Net revenue was $39,000, with an operating loss of $6.0 million and net loss of $4.4 million, or $0.08 per share attributable to common stockholders.
Cash rose to $25.3 million as of March 31, 2026, supported by an upsized public offering for up to $78.0 million, including $30.0 million in gross proceeds at closing and additional potential proceeds from milestone-linked warrants. The company completed enrollment of its U.S. pivotal trial, implanting the 56th and final patient, and early six‑month data from the first 10 patients showed no study-defined serious adverse events and improved CNC word recognition from 15.2% to 39.2%, supporting its path toward a planned PMA submission.
Envoy Medical, Inc. director Chas McKhann received a grant of stock options covering 100,000 shares of Class A common stock. The options have an exercise price of $0.72 per share and expire on April 15, 2036.
Beginning May 15, 2026, these options vest pro rata on the 15th of each month over 36 consecutive months. After this grant, McKhann holds stock options for 100,000 underlying shares directly.
Envoy Medical, Inc. director Chas McKhann filed an initial Form 3 statement of beneficial ownership for the company’s common stock. The filing shows no reported purchases, sales, derivative exercises, gifts, tax withholdings, restructurings, or other transactions, and no current derivative positions listed.
Envoy Medical, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to correct a typographical error in the consent of Grant Thornton LLP, its independent registered public accounting firm. The amendment also includes updated officer certifications under Section 302 of the Sarbanes-Oxley Act and makes no other changes to the original report.
The company reported an aggregate market value of approximately $12.7 million for Class A common stock held by non-affiliates as of its most recently completed fiscal quarter, and had 76,881,110 Class A shares outstanding as of March 20, 2026.